This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Heat Biologics [HTBX], a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies to treat a wide variety of cancers, will visit the NASDAQ MarketSite in Times Square in celebration of its initial public offering (IPO), which will occur today, July 24, 2013, on The NASDAQ Stock Market.
In honor of the occasion,
Jeff Wolf, CEO will ring the Closing Bell.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Wednesday, July 24, 2013 – 3:45 p.m. to 4:00 p.m. ET
Contact: Rhonda Chiger (917) 322-2569
firstname.lastname@example.orgNASDAQ MarketSite: Christine Barna (646) 441-5310
Christine.Barna@nasdaqomx.comFeed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Heat Biologics [HTBX]:
Heat Biologics (
www.heatbio.com ) is a clinical-stage biopharmaceutical company focused on developing its novel off-the-shelf
ImPACT therapeutic vaccines to combat a wide range of cancers. Our proprietary
ImPACT Therapy is being designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat shock protein gp-96 is a chaperone protein found in all human cells. Heat's lead compound, HS-110, will be entering Phase 2 trials against non-small cell lung cancer and its second product candidate, HS-410 will be entering Phase 1/2 clinical trials against bladder cancer.
About NASDAQ OMX Group:
The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets including 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-55 microsecond average speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,300 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit
www.nasdaqomx.com . Follow us on Facebook (
http://www.facebook.com/NASDAQ ) and Twitter (
http://www.twitter.com/nasdaqomx ). (Symbol: NDAQ and member of S&P 500)